In neonatal intensive care units (NICUs) worldwide, fluid management remains a cornerstone of supportive therapy, particularly in critically ill neonates. A recent study, published in the Journal of Perinatology, explores an individualized and precision medicine-based approach to the selection of balanced crystalloid solutions compared to “normal” saline (NS) boluses. This research marks a potential paradigm shift, emphasizing the tailored use of intravenous fluids in newborns, considering their specific clinical scenarios rather than a one-size-fits-all approach.
Fluid therapy in neonates is complex due to their unique physiological characteristics, such as immature renal function and a delicate acid-base balance. Traditionally, NS has been the default intravenous solution for fluid boluses, largely because of its availability and familiarity. However, NS is hyperchloremic and can potentially exacerbate metabolic acidosis and chloride overload, especially in vulnerable infants. The study presents a compelling argument favoring the nuanced use of balanced crystalloids, which are formulated to more closely mimic plasma electrolyte composition and reduce electrolyte and acid-base disturbances.
The authors advocate for the preferential use of balanced crystalloid solutions in neonates exhibiting signs of hypoperfusion coupled with known or suspected fluid losses leading to low preload states. These circumstances frequently occur in infants experiencing significant dehydration or hemorrhage. Balanced solutions, containing lower chloride content and added bicarbonate precursors, help restore intravascular volume without precipitating the detrimental hyperchloremic metabolic acidosis seen with NS. This is particularly relevant in neonates with preexisting metabolic derangements, where the acid-base balance is precarious.
Moreover, metabolic acidosis with an elevated chloride level or low bicarbonate may also trigger the preference for balanced crystalloids. These solutions, often termed “buffered solutions,” can ameliorate the acidotic state by providing a more physiologically balanced electrolyte load compared to NS. By contrast, NS tends to exacerbate acidosis due to its high chloride content and lack of buffering capacity. The study’s practical recommendations highlight balancing the risks of worsening acidosis against the operational aspects of fluid delivery in the NICU setting.
Nonetheless, the research acknowledges clinical scenarios in which NS remains the fluid of choice. For neonates with limited intravenous access or those requiring concurrent administration of other intravenous solutions containing calcium, phosphate, or citrate, NS remains compatible and thus preferred. Additionally, in acute resuscitation settings such as the delivery room, where rapid administration and availability are critical, NS is often the first-line crystalloid due to its ubiquitous availability and compatibility with neonatal resuscitation protocols.
The study includes a quick reference table summarizing these clinical scenarios alongside the recommended fluid bolus type. Though not reproduced here, this guide serves as a valuable tool for clinicians, facilitating rapid decision-making in emergent or complex care situations. Importantly, these practical algorithmic approaches underscore the study’s thrust towards precision medicine — optimizing interventions based on individual patient characteristics and dynamic clinical needs.
From a biochemical perspective, balanced crystalloids such as lactated Ringer’s or Plasma-Lyte address the neonatal susceptibility to electrolyte and acid-base imbalances more effectively than NS. These solutions contain electrolytes in concentrations closer to plasma, reducing the physiological stress induced by chloride overload. For neonates, especially premature infants with immature kidneys, maintaining this delicate balance is crucial to prevent complications such as renal impairment and systemic acidosis, which can complicate recovery and increase mortality risk.
The physiological rationale behind balanced crystalloids situates itself within the broader context of neonatal pathophysiology. Hypoperfusion states common in NICU patients, including sepsis, hypovolemia, and shock, benefit from volume expansion that also optimizes acid-base homeostasis. Balanced fluids mitigate the risk of iatrogenic acid-base disturbances, supporting organ perfusion without added physiological insult. This precision approach fosters better clinical outcomes by minimizing secondary complications.
Furthermore, the article highlights that balanced crystalloids are not a panacea and that clinical trade-offs exist. The compatibility of other necessary parenteral solutions often limits their use, demanding a judicious selection based on vascular access and fluid compatibility. The practical recommendation to prefer NS in constrained clinical logistics underscores the importance of individualized therapy and clinical pragmatism.
Intriguingly, the study calls into question the traditional dogma favoring NS undeniable in many neonatal scenarios due to convention rather than evidence-based superiority. This research compels the neonatal community to reconsider entrenched fluid management protocols, potentially integrating balanced crystalloids as a new standard for select indications, bolstered by precision-medicine principles.
The timing of fluid administration also emerges as a vital factor. Emergency resuscitation requires rapid fluid access, where availability and ease take precedence. However, once the neonate is stabilized, precision in selecting fluid type based on metabolic needs and ongoing clinical assessment becomes paramount. This dynamic approach could significantly influence outcomes by tailoring fluid therapy as the clinical picture evolves.
Preventing complications such as hyperchloremic metabolic acidosis is particularly crucial in neonates, who are disproportionately sensitive due to their immature organ systems. The data suggest that balanced fluids reduce this risk by avoiding chloride overload, thus aligning with goals of limiting iatrogenic harm. This insight elevates the importance of revisiting intravenous fluid protocols within NICUs globally.
Additionally, the paper underscores the need for further clinical trials to validate and refine these recommendations, particularly in diverse neonatal populations. Such investigations could elucidate the long-term benefits of balanced fluids in terms of renal function preservation, acid-base stability, and overall neonatal morbidity and mortality. Until then, the authors propose this precision approach as a practical and scientifically justified interim guideline.
In conclusion, this study heralds a thoughtful, nuanced approach to fluid bolus selection in neonates, emphasizing the balance between physiological fidelity and clinical pragmatism. As neonatal care continues to embrace precision medicine, fluid management strategies will likely evolve toward individualized protocols tailored to each neonate’s unique metabolic and hemodynamic milieu. This research invites neonatologists to rethink fluid therapy beyond tradition, opening avenues for improved care and outcomes driven by meticulous physiological understanding.
Ultimately, the integration of balanced crystalloid solutions into NICU practice demands concerted efforts in education, protocol development, and resource allocation. These efforts will be essential to transition from NS-dominated regimens toward a more physiologically sensitive and precision-based fluid therapy landscape, poised to enhance neonatal survival and long-term health trajectories.
Subject of Research:
Precision-medicine based approach to the use of balanced crystalloid solutions versus normal saline in neonatal fluid bolus therapy.
Article Title:
Balanced fluid bolus: Should we prefer balanced crystalloids over “normal” saline?
Article References:
Carrigan, K., Lakshminrusimha, S. Balanced fluid bolus: Should we prefer balanced crystalloids over “normal” saline?.
J Perinatol (2026). https://doi.org/10.1038/s41372-026-02622-z
Image Credits: AI Generated
DOI: 13 March 2026
